- WuXi Vaccines is investing $240 million in a new manufacturing facility in Dundalk, Ireland.
- The facility will include drug substance manufacturing (MFG15), drug product manufacturing (DP5), and Quality Control labs (QC).
- The project follows a 20-year manufacturing Letter of Intent signed earlier this year.
- The facility will create 200 highly-skilled jobs and is subject to planning approval.
Investment and Facility Details
WuXi Vaccines is set to invest $240 million in a new vaccine manufacturing facility in Dundalk, Ireland. This facility will include drug substance manufacturing (MFG15), drug product manufacturing (DP5), and Quality Control labs (QC). The investment follows a 20-year manufacturing Letter of Intent (LOI) signed earlier this year.
Location and Timeline
The new facility will be located within the WuXi Biologics Campus, adjacent to the “Factory of the Future” biologics drug substance manufacturing facility, which is scheduled for commercial manufacturing in 2021. The project is subject to planning approval.
Job Creation
The new facility will create 200 highly-skilled jobs in Dundalk. This is in addition to the 400 roles announced last year by WuXi Biologics for the same location.
Industry Impact
This will be the first vaccines contract manufacturing facility in Ireland, significantly strengthening the country's life sciences ecosystem and reinforcing its manufacturing capabilities. The facility will supply a vaccine product for a large global pharmaceutical company, targeting the global market.
